Notice to Extend the Submission Period to the National Cancer Institute (NCI) for PA-18-906, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
PA-18-906
Notice Number: NOT-CA-20-041
Key Dates
Release Date: March 23, 2020
PA-18-906
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to inform interested applicants that the submission period to the National Cancer Institute (NCI) for PA-18-906 “Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)” has been extended in the fiscal year 2020.
The new submission period will now be February 1 April 30, 2020.
The NCI guidelines can be found here.
All other aspects of PA-18-906 remain unchanged.
Inquiries
Please direct all inquiries to:
Alison Lin, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6177
Email: [email protected]
Department of Health
and Human Services (HHS)
and Human Services (HHS)
